MK-8722

**MK-8722** is a potent, orally bioavailable, small molecule pan-activator of AMP-activated protein kinase (AMPK), capable of directly activating all 12 AMPK complexes in mammalian cells[1][3][7][8]. Developed primarily as a systemic metabolic modulator, it was investigated for its ability to lower blood glucose and improve insulin sensitivity, based on strong effects in rodent and primate models of diabetes[1][7]. Mechanistically, MK-8722 activates both β1- and β2-containing AMPK complexes directly, resulting in increased phosphorylation of downstream targets like acetyl-CoA carboxylase (ACC), enhancing glucose uptake in skeletal muscle and altering lipid metabolism[1]. Preclinical studies also demonstrated its ability to induce autophagy and modulate lipid metabolism, with observed antitumor effects in epithelial ovarian cancer models via fatty acid synthase (FASN) pathway modulation and autophagy inhibition[2]. Despite these benefits, chronic administration led to dose-dependent cardiac hypertrophy in animal models, raising significant safety concerns and precluded advancement to clinical trials[4][5][7]. MK-8722 is primarily used as a research tool compound for AMPK biology.